- Home
- LILAK vs AKRO Comparison
LILAK vs AKRO Comparison
Compare LILAK & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- AKRO
- Stock Information
- Founded
- LILAK 2017
- AKRO 2017
- Country
- LILAK Bermuda
- AKRO United States
- Employees
- LILAK N/A
- AKRO N/A
- Industry
- LILAK Cable & Other Pay Television Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- LILAK Telecommunications
- AKRO Health Care
- Exchange
- LILAK Nasdaq
- AKRO Nasdaq
- Market Cap
- LILAK 1.1B
- AKRO 3.9B
- IPO Year
- LILAK N/A
- AKRO 2019
- Fundamental
- Price
- LILAK $6.60
- AKRO $51.77
- Analyst Decision
- LILAK Buy
- AKRO Strong Buy
- Analyst Count
- LILAK 3
- AKRO 6
- Target Price
- LILAK $10.27
- AKRO $82.50
- AVG Volume (30 Days)
- LILAK 1.1M
- AKRO 1.7M
- Earning Date
- LILAK 08-05-2025
- AKRO 08-08-2025
- Dividend Yield
- LILAK N/A
- AKRO N/A
- EPS Growth
- LILAK N/A
- AKRO N/A
- EPS
- LILAK N/A
- AKRO N/A
- Revenue
- LILAK $4,441,000,000.00
- AKRO N/A
- Revenue This Year
- LILAK $2.45
- AKRO N/A
- Revenue Next Year
- LILAK $3.11
- AKRO N/A
- P/E Ratio
- LILAK N/A
- AKRO N/A
- Revenue Growth
- LILAK N/A
- AKRO N/A
- 52 Week Low
- LILAK $4.23
- AKRO $21.02
- 52 Week High
- LILAK $10.93
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- LILAK 74.11
- AKRO 49.14
- Support Level
- LILAK $5.78
- AKRO $51.08
- Resistance Level
- LILAK $6.53
- AKRO $57.35
- Average True Range (ATR)
- LILAK 0.24
- AKRO 2.21
- MACD
- LILAK 0.09
- AKRO -0.81
- Stochastic Oscillator
- LILAK 96.21
- AKRO 11.08
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.